FDA Warning Letter to Clover Meds Over White-Labeled GLP-1 Products and "FDA-Licensed Facilities" Claim
On June 8, 2026, FDA issued a warning letter to Clover Meds after a March 2026 review of clovermeds.com, which offers compounded semaglutide and tirzepatide products. FDA says pictured labels identify "Clover Meds" as if it were the compounder "when in fact it is not," and that the claim its products are sourced from "FDA-licensed Facilities" is "false and misleading," because the FD&C Act establishes no "FDA-approved" or "FDA-licensed" designation for compounding facilities. FDA requested a written response within 15 business days.
What this meansFDA does not approve or license compounding pharmacies, so "FDA-approved pharmacy" language on a provider's site is worth questioning — how a provider describes its pharmacy partners says a lot about how carefully it operates.
Source: FDA original ↗